Mitral valvuloplasty reduced early mortality by 29% compared to mitral valve replacement in patients with rheumatic mitral valve disease (OR 0.71; 95% CI 0.54-0.92).
Systematic Review (n=15,271)
Does mitral valvuloplasty (MVP) or percutaneous mitral balloon commissurotomy (PMBC) improve mortality and reduce reoperation compared to mitral valve replacement (MVR) in patients with rheumatic mitral valve disease?
Composite mitral valvuloplasty (MVP) offers superior early and follow-up mortality outcomes compared to mitral valve replacement (MVR) and lower reoperation rates than percutaneous mitral balloon commissurotomy (PMBC) in rheumatic mitral valve disease.
Effect estimate: OR 0.71 (95% CI 0.54-0.92)
Absolute Event Rate: 0.71% vs 1%
Abstract This systematic review compared the efficacies of percutaneous mitral balloon commissurotomy (PMBC), mitral valvuloplasty (MVP), and mitral valve replacement (MVR) in patients with rheumatic mitral valve disease. Data from 15,271 patients across 23 cohort studies and randomized controlled trials were analyzed. Based on the results of the network meta-analysis, MVP demonstrated a lower early mortality rate odds ratio (OR), 0.71; 95% confidence interval (CI): 0.54–0.92, follow-up mortality rate (OR: 0.84; 95% CI: 0.72-0.99), and complication rate (OR: 0.75; 95% CI: 0.64-0.88) compared to MVR. The follow-up reoperation rate in the MVP group was significantly lower than that in the PMBC group (OR: 0.49; 95% CI: 0.30–0.80). The optimal surgical strategy should be tailored to achieve better prognoses.
Liu et al. (Fri,) conducted a systematic review in Patients with rheumatic mitral valve disease undergoing surgical intervention (n=15,271). Mitral valvuloplasty (MVP) vs. Mitral valve replacement (MVR) and percutaneous mitral balloon commissurotomy (PMBC) was evaluated on Early mortality rate (OR 0.71, 95% CI 0.54-0.92). Mitral valvuloplasty reduced early mortality by 29% compared to mitral valve replacement in patients with rheumatic mitral valve disease (OR 0.71; 95% CI 0.54-0.92).